Progressive Supranuclear Palsy: Medications and Promising New Trials

Progressive Supranuclear Palsy: Medications and Promising New Trials

Progressive supranuclear palsy (PSP) is a rare neurological condition that affects movement, balance, speech, vision, and cognition. It is caused by the degeneration of brain cells, leading to an accumulation of a protein called tau. PSP shares similar symptoms with Parkinson's disease, but it progresses more rapidly and typically has a poorer prognosis.

There is currently no cure for PSP, and treatments mainly focus on managing symptoms and improving the quality of life for patients. However, researchers are continuously exploring new medications and clinical trials to find more effective treatments. This blog post will delve into the medications currently used to manage PSP and highlight some promising clinical trials that offer hope for the future.

Current Medications for PSP

  1. Levodopa

Levodopa is a medication used to manage Parkinson's disease, and it has also been used to treat the motor symptoms of PSP. Levodopa is converted into dopamine in the brain, which helps regulate movement. Unfortunately, levodopa has limited effectiveness in PSP patients, as it often provides only mild and temporary relief from symptoms.

  1. Antidepressants

Depression is a common non-motor symptom in PSP patients. Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, can help alleviate depressive symptoms and improve the quality of life. Common SSRIs include fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil), while examples of tricyclic antidepressants are amitriptyline and nortriptyline.

  1. Anticholinergics

Anticholinergic medications can help manage some of the movement-related symptoms of PSP by blocking the action of acetylcholine, a neurotransmitter involved in muscle contractions. However, these medications can cause side effects like dry mouth, blurred vision, and constipation, making them less suitable for long-term use. Examples of anticholinergics are trihexyphenidyl (Artane) and benztropine (Cogentin).

  1. Botulinum toxin

Botulinum toxin injections, commonly known as Botox, can help manage involuntary eye closure (blepharospasm) and other eye movement disorders in PSP patients. The toxin works by temporarily paralyzing the muscles responsible for these involuntary movements.

  1. Amantadine

Amantadine is an antiviral medication that may help alleviate some of the motor symptoms of PSP, such as rigidity and bradykinesia (slow movement). However, its effectiveness is limited, and it may cause side effects like insomnia, dizziness, and hallucinations.

Promising Clinical Trials for PSP

Despite the limitations of current medications, there is reason to be hopeful about future treatment options for PSP. Several clinical trials are underway to investigate the safety and efficacy of new drugs that target the underlying causes of the disease. Some of the most promising clinical trials include:

  1. ABBV-8E12 (Taucilizumab)

ABBV-8E12 is a humanized monoclonal antibody that targets the abnormal tau protein. The drug aims to prevent the accumulation of tau in the brain, which could potentially slow the progression of PSP. A Phase 2 clinical trial of ABBV-8E12 (NCT03068468) showed encouraging results, and a Phase 3 trial (NCT04270489) is currently underway to further evaluate the safety and efficacy of the drug in PSP patients.

  1. Anle138b

Anle138b is a small molecule that has been shown to reduce the accumulation of tau protein in preclinical studies. It is believed to work by blocking the aggregation of tau, thereby preventing the formation of toxic protein deposits in the brain. A Phase 1 clinical trial (NCT04558462) has been completed to evaluate the safety, tolerability, and pharmacokinetics of Anle138b in healthy volunteers. The results of this trial will determine whether Anle138b will progress to further clinical testing in PSP patients.

  1. PRX002/RG7935 (Semorinemab)

PRX002/RG7935 is another monoclonal antibody that targets tau protein, with the aim of reducing its accumulation in the brain. A Phase 2 clinical trial (NCT03100149) known as the PASADENA study was conducted to evaluate the safety and efficacy of PRX002/RG7935 in patients with early Parkinson's disease. Although the trial did not meet its primary endpoint, secondary endpoints showed some positive trends, which may warrant further investigation of the drug in PSP and other tauopathies.

  1. BIIB092 (Gosuranemab)

BIIB092 is a monoclonal antibody that binds to extracellular tau, preventing the spread of tau pathology between brain cells. The drug has shown promise in preclinical studies and has been tested in a Phase 2 clinical trial (NCT03688972) for PSP patients. Unfortunately, the trial did not meet its primary endpoint, but further analysis of the data may provide insights that could guide the development of future tau-targeting therapies.

  1. Nilotinib

Nilotinib is a tyrosine kinase inhibitor that is currently approved for the treatment of certain types of leukemia. Preclinical studies have suggested that nilotinib may also have neuroprotective effects by promoting the clearance of toxic proteins, including tau, from the brain. A Phase 2 clinical trial (NCT02947893) was conducted to evaluate the safety and efficacy of nilotinib in patients with Parkinson's disease and dementia with Lewy bodies. While the trial did not meet its primary endpoint, it did show some positive trends, which may encourage further investigation of nilotinib in PSP and other neurodegenerative disorders.

While there is currently no cure for progressive supranuclear palsy, ongoing research and clinical trials offer hope for the development of more effective treatments in the future. Current medications can provide some symptom relief and improve the quality of life for PSP patients, but they do not address the underlying cause of the disease. The clinical trials mentioned in this post represent just a few examples of the many research efforts aimed at finding new ways to target the pathological processes that drive PSP. As our understanding of the disease continues to grow, so too does the potential for breakthroughs that could significantly improve the lives of those affected by this devastating condition.

Back to blog

39 comments

My husband gas just been diagnosed with PSP. Please keep us informed of any trials he could possibly participate in.

Linda Alexander

Please visit https://clinicaltrials.gov for the most updated info on past, current and upcoming trials.

Thank you
Laura Louizos

Laura

Hello, my son 55, was diagnosed with psp in 2023. I read about the “promising “ phase #3. When is it going to be completed.
He would be interested in the clinical trail. Can you please send us some informations.
Could you please let us know all recent developments. Thank you so much.

Renata cocco

How can I enroll my brother in this trial?
He’s been diagnosed with psp?

Santina Marras

My father is diagnosed with psp in 2022. His condition is worsening and now he can barely walk. His eye sight has worsened and he is developing body pain. He keeps crying thinking that he is soon going to die. He lives in India and is given levodopa as medication. He is very weak to do any exercises given by physiotherapist. Can some one please tell how far are we with finding a cure for psp?Do you have any tips on how to help my dear father?

Neethu Krishnan

Leave a public comment:

Please note, comments need to be approved before they are published.

  • Understanding Atypical Parkinsonism: PSP, MSA, CBD, and DLB

    Understanding Atypical Parkinsonism: PSP, MSA, ...

    Laura Louizos

    When we talk about Parkinsonism, most people immediately think of Parkinson's Disease (PD). However, there exists a group of less common disorders known as atypical parkinsonism, each with its unique...

    Understanding Atypical Parkinsonism: PSP, MSA, ...

    Laura Louizos

    When we talk about Parkinsonism, most people immediately think of Parkinson's Disease (PD). However, there exists a group of less common disorders known as atypical parkinsonism, each with its unique...

  • Introducing "Faces and Voices of Atypical Parkinsonism" by CCF

    Introducing "Faces and Voices of Atypical Parki...

    Laura Louizos

    At the Coleen Cunningham Foundation (CCF), we've embarked on a new journey to bring awareness to the lesser-known side of Parkinsonism - the atypical forms. Our latest campaign, "Faces and...

    Introducing "Faces and Voices of Atypical Parki...

    Laura Louizos

    At the Coleen Cunningham Foundation (CCF), we've embarked on a new journey to bring awareness to the lesser-known side of Parkinsonism - the atypical forms. Our latest campaign, "Faces and...

  • Understanding the Stages of Dementia with Lewy Bodies (DLB)

    Understanding the Stages of Dementia with Lewy ...

    Laura Louizos

    Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, motor symptoms similar to Parkinson's disease, and fluctuating alertness. The progression of DLB can...

    Understanding the Stages of Dementia with Lewy ...

    Laura Louizos

    Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, motor symptoms similar to Parkinson's disease, and fluctuating alertness. The progression of DLB can...

  • Understanding the Stages of Multiple System Atrophy (MSA)

    Understanding the Stages of Multiple System Atr...

    Laura Louizos

    Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting several brain regions, resulting in symptoms related to movement, autonomic function, and sleep. Here's how the progression of MSA...

    Understanding the Stages of Multiple System Atr...

    Laura Louizos

    Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting several brain regions, resulting in symptoms related to movement, autonomic function, and sleep. Here's how the progression of MSA...

1 of 4